公开(公告)号：US20210346361A1

公开(公告)日：2021-11-11

申请号：US17128500

申请日：2020-12-21

申请人： CHEMOCENTRYX, INC. ,  THE REGENTS OF THE UNIVERSITY OF CALIFORNIA

发明人： James J. CAMPBELL ,  Rajinder SINGH ,  Samuel HWANG ,  Xuesong WU

IPC分类号： A61K31/4433 ,  C07K16/28 ,  A61K31/496 ,  A61P35/00 ,  A61K39/395

摘要： The present disclosure provides, inter alia, methods of treating a solid-tumor by administering an effective amount of a Chemokine Receptor 2 (CCR2) antagonist. Also provided herein are methods of reducing the number of macrophages in a solid tumor microenvironment, said method comprising administering effective amount of a Chemokine Receptor 2 (CCR2) antagonist. In an additional aspect, the current disclosure further provides methods of increasing the number CD8+ T cells in a solid tumor microenvironment, said method comprising administering effective amount of a Chemokine Receptor 2 (CCR2) antagonist. In some embodiments, the CCR2 antagonist has the formula I or Formula III:

公开(公告)号：US20190269664A1

公开(公告)日：2019-09-05

申请号：US16358329

申请日：2019-03-19

申请人： CHEMOCENTRYX, INC. ,  THE REGENTS OF THE UNIVERSITY OF CALIFORNIA

发明人： James J. CAMPBELL ,  Rajinder SINGH ,  Samuel HWANG ,  Xuesong WU

IPC分类号： A61K31/4433 ,  A61P35/00 ,  A61K31/496 ,  C07K16/28

摘要： The present disclosure provides, inter alia, methods of treating a solid-tumor by administering an effective amount of a Chemokine Receptor 2 (CCR2) antagonist. Also provided herein are methods of reducing the number of macrophages in a solid tumor microenvironment, said method comprising administering effective amount of a Chemokine Receptor 2 (CCR2) antagonist. In an additional aspect, the current disclosure further provides methods of increasing the number CD8+ T cells in a solid tumor microenvironment, said method comprising administering effective amount of a Chemokine Receptor 2 (CCR2) antagonist. In some embodiments, the CCR2 antagonist has the formula I or Formula III:

公开(公告)号：US20220241290A1

公开(公告)日：2022-08-04

申请号：US17481829

申请日：2021-09-22

申请人： CHEMOCENTRYX, INC. ,  THE REGENTS OF THE UNIVERSITY OF CALIFORNIA

发明人： James J. CAMPBELL ,  Rajinder SINGH ,  Samuel HWANG ,  Xuesong WU

IPC分类号： A61K31/536 ,  A61P35/00 ,  A61K45/06 ,  A61K31/4433 ,  A61K31/453

摘要： The present disclosure provides, inter alia, methods of treating a solid-tumor by administering an effective amount of a Chemokine Receptor 2 (CCR2) antagonist. Also provided herein are methods of reducing the number of macrophages in a solid tumor microenvironment, said method comprising administering effective amount of a Chemokine Receptor 2 (CCR2) antagonist. In an additional aspect, the current disclosure further provides methods of increasing the number CD8+ T cells in a solid tumor microenvironment, said method comprising administering effective amount of a Chemokine Receptor 2 (CCR2) antagonist. In some embodiments, the CCR2 antagonist has the formula I:

公开(公告)号：US20190209573A1

公开(公告)日：2019-07-11

申请号：US16241391

申请日：2019-01-07

申请人： CHEMOCENTRYX, INC. ,  THE REGENTS OF THE UNIVERSITY OF CALIFORNIA

发明人： James J. CAMPBELL ,  Rajinder SINGH ,  Samuel HWANG ,  Xuesong WU

IPC分类号： A61K31/536 ,  A61K31/4433 ,  A61K45/06 ,  A61P35/00

CPC分类号： A61K31/536 ,  A61K31/4433 ,  A61K45/06 ,  A61P35/00

摘要： The present disclosure provides, inter alia, methods of treating a solid-tumor by administering an effective amount of a Chemokine Receptor 2 (CCR2) antagonist. Also provided herein are methods of reducing the number of macrophages in a solid tumor microenvironment, said method comprising administering effective amount of a Chemokine Receptor 2 (CCR2) antagonist. In an additional aspect, the current disclosure further provides methods of increasing the number CD8+ T cells in a solid tumor microenvironment, said method comprising administering effective amount of a Chemokine Receptor 2 (CCR2) antagonist. In some embodiments, the CCR2 antagonist has the formula I: